Drugs / ATLCAR.CD30.CCR4
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03602157 | Oct 2018 → Dec 2025 overdue | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, Sezary syndrome, immunoproliferative disorder, lymphomatoid papulosis +3 | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06090864 | Apr 2024 → Jul 2026 overdue | Hodgkins lymphoma | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATLCAR.CD30.CCR4 | “ATLCAR.CD30.CCR4 cells infusion for the eligible subjects after depletion chemotherapy.” NCT06090864 ↗ |
| Modality | Cell therapy | “CAR-T cells” NCT03602157 ↗ |
| Route | Intravenous | “The cells will be administered by a licensed provider (oncology nurse or physician) via intravenous injection over 1-10 minutes through either a peripheral or a central line.” NCT03602157 ↗ |